RetailBook Offer

• The Issue Price for the new Ordinary Shares is 1.5 pence per new Ordinary Share, representing a discount of 17.8 per cent to the closing mid-price of the Company's existing Ordinary Shares on 26 March 2025;
• The RetailBook Offer is open to existing shareholders only;
• There is a minimum subscription of £50 per investor in the RetailBook Offer;
• No commission will be charged by RetailBook on applications to the RetailBook Offer.

The RetailBook Offer

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company is pleased to announce a conditional retail offer of new ordinary shares in the capital of the Company ("Ordinary Shares") via RetailBook (the "RetailBook Offer") at an issue price of 1.5 pence per new Ordinary Share (the "Issue Price"), being a discount of 17.8 per cent to the closing mid-price of the Company's existing Ordinary Shares on 26 March 2025. The Company has separately announced it is raising gross proceeds of £1.0 million by means of a subscription (the "Subscription", together with the RetailBook Offer, the "Fundraise") for 66,666,666 Ordinary Shares by the market making arm of Peel Hunt LLP (the "Subscription Shares") at the Issue Price. For the avoidance of doubt, the RetailBook Offer is not part of the Subscription.

The RetailBook Offer is conditional on the new Ordinary Shares to be issued pursuant to the RetailBook Offer and the Subscription Shares being admitted to trading on AIM ("Admission"). Admission is expected to take place at 8:00 a.m. on 3 April 2025.

The RetailBook Offer will not be completed without the Subscription also being completed.

The net proceeds from the Fundraise will provide genedrive with additional working capital as it actively pursues a broad range of growing commercial opportunities in the UK and internationally at the present time, including both commercial sales and potential non-dilutive grant income. CE-IVD certification for genedrive's CYP2C19 test, which is on track for April 2025, will also enable in-country registration and subsequently sales of the test to commence outside of the UK and genedrive is particularly encouraged by opportunities presented in the Middle East region, where it has focused significant efforts and expenditure to understand market access and reimbursement routes as well as identification of primary target hospitals, opinion leaders and healthcare organisations and will update further in due course as opportunities are converted as appropriate.

Reasons for the RetailBook Offer

The Company values its retail shareholder base and believes that it is in the best interests of shareholders as well as wider stakeholders, to provide retail investors in the United Kingdom, the opportunity to participate in the RetailBook Offer.

The RetailBook Offer is open to existing shareholders resident and physically located in the United Kingdom following release of this announcement. The RetailBook Offer is expected to close at 5 p.m. on 31 March 2025 and may close earlier at the discretion of the Company or if it is oversubscribed.

Eligible investors can participate through RetailBook's partner network of investment platforms, retail brokers and wealth managers, subject to such partners' participation. Participating partners include:

• AJ Bell;
• Hargreaves Lansdown; and
• interactive investor

Eligibility for the RetailBook Offer

Some partners may only accept applications from existing customers.

There is a minimum subscription of £50 per investor. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges. Note, no commission will be charged to investors by RetailBook in connection with the RetailBook Offer.